Detalhe da pesquisa
1.
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
HIV Med
; 24(2): 202-211, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35945163
2.
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
J Med Virol
; 93(6): 3985-3990, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33300183
3.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
AIDS Res Ther
; 16(1): 23, 2019 08 29.
Artigo
Inglês
| MEDLINE | ID: mdl-31464642
4.
Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study.
Antivir Ther
; 29(2): 13596535241248282, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38725258
5.
Bioequivalence of a Pediatric Fixed-Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open-Label, Randomized, Replicate Crossover Study.
Clin Pharmacol Drug Dev
; 12(11): 1060-1068, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37335552
6.
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
HIV Res Clin Pract
; 21(6): 151-167, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33528318
7.
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
AIDS Res Hum Retroviruses
; 36(1): 48-57, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31516033
8.
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
AIDS
; 34(5): 707-718, 2020 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31833849
9.
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Clin Pharmacol Drug Dev
; 8(4): 480-491, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30412360
10.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
HIV Res Clin Pract
; 20(1): 24-33, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31303147
11.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Antiviral Res
; 170: 104543, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31279073
12.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Lancet HIV
; 5(1): e23-e34, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28993180
13.
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
AIDS
; 32(11): 1431-1442, 2018 07 17.
Artigo
Inglês
| MEDLINE | ID: mdl-29683855